Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 9/20 | 0.67 |
| ▸ | HTR1D | P28221 | 9/20 | 0.67 |
| ▸ | HTR1B | P28222 | 9/20 | 0.67 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.54 |
| ▸ | CYSLTR1 | Q9Y271 | 5/20 | 0.54 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.54 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7812705 | 0.90 | HTR1A (0.62) | HTR1AHTR1DHTR1BSLC6A9KCNH2 | |
| SCHEMBL8186003 | 0.86 | HTR1A (0.66) | HTR1AHTR1DHTR1BSLC6A9KCNH2 | |
| SCHEMBL7803791 | 0.86 | HTR1A (0.69) | HTR1AHTR1DHTR1BSLC6A9KCNH2 | |
| SCHEMBL7803798 | 0.84 | HTR1A (0.64) | HTR1AHTR1DHTR1BSLC6A9KCNH2 | |
| SCHEMBL6312894 | 0.83 | HTR1A (0.75) | HTR1AHTR1DHTR1BSLC6A9KCNH2 | |
| SCHEMBL7816481 | 0.83 | HTR1A (0.67) | HTR1AHTR1DHTR1BSLC6A9KCNH2 | |
| SCHEMBL8186008 | 0.83 | HTR1A (0.61) | HTR1AHTR1DHTR1BSLC6A9KCNH2 | |
| SCHEMBL7812501 | 0.82 | HTR1A (0.66) | HTR1AHTR1DHTR1BSLC6A9KCNH2 | |
| SCHEMBL7812844 | 0.81 | HTR1A (0.62) | HTR1AHTR1DHTR1BSLC6A9KCNH2 | |
| SCHEMBL8571961 | 0.81 | HTR1A (0.55) | HTR1AHTR1DHTR1BSLC6A9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| US-20050080090-A1 | Naphthalene derivatives | CHENARD BERTRAND L (US) | 2005-04-14 | — | — | US | disclosed |
| US-20020058811-A1 | Naphthalene derivatives | CHENARD BERTRAND L (US) | 2002-05-16 | — | — | US | disclosed |
| EP-0767782-B1 | ARYL AND HETEROARYL ALKOXYNAPHTHALENE DERIVATIVES | PFIZER (US) | 2001-10-31 | — | — | EP | disclosed |
| US-20010004669-A1 | Pyrazinyl-substituted naphthalene derivatives | CHENARD BERTRAND L (US) | 2001-06-21 | — | — | US | disclosed |
| EP-0689536-B1 | NAPHTHALENE DERIVATIVES | PFIZER (US) | 2001-05-23 | — | — | EP | disclosed |
| CN-1064350-C | Aryl and heteroaryl alkoxynaphtalene derivatives | PFIZER (US) | 2001-04-11 | — | — | CN | disclosed |
| US-6166020-A | Aryl and heteroaryl alkoxynaphthalene derivatives | PFIZER INC. (US) | 2000-12-26 | — | — | US | disclosed |
| EP-0701819-B1 | Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER (US) | 2000-08-16 | — | — | EP | disclosed |
| US-5821245-A | Use of naphthalene derivatives in treating lung carcinoma | PFIZER INC. (US) | 1998-10-13 | — | — | US | disclosed |
| EP-0795328-A1 | Use of naphthalene derivatives in treating lung carcinoma | PFIZER INC. (US) | 1997-09-17 | — | — | EP | disclosed |
| CN-1151729-A | Aryl and heteroaryl alkoxynaphtalene derivatives | PFIZER (US) | 1997-06-11 | — | — | CN | disclosed |
| EP-0767782-A1 | ARYL AND HETEROARYL ALKOXYNAPHTHALENE DERIVATIVES | PFIZER INC. (US) | 1997-04-16 | — | — | EP | disclosed |
| US-5597826-A | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER INC. (US) | 1997-01-28 | — | — | US | disclosed |
| EP-0701819-A2 | Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER INC. (US) | 1996-03-20 | — | — | EP | disclosed |
| WO-1996000720-A1 | ARYL AND HETEROARYL ALKOXYNAPHTHALENE DERIVATIVES | PFIZER INC. (US) | 1996-01-11 | — | — | WO | disclosed |
| EP-0689536-A1 | NAPHTHALENE DERIVATIVES | PFIZER INC. (US) | 1996-01-03 | — | — | EP | disclosed |
| WO-1994021619-A1 | NAPHTHALENE DERIVATIVES | PFIZER INC. (US) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010004669-A1 | Pyrazinyl-substituted naphthalene derivatives | HTR4, HCRTR2, CNR2 | HTR1A 13/4885HTR1D 22/4885HTR1B 10/4885 |
| US-20050080090-A1 | Naphthalene derivatives | HTR4, NPY4R, HCRTR1 | HTR1A 9/4885HTR1D 21/4885HTR1B 12/4885 |
| US-20020058811-A1 | Naphthalene derivatives | HTR4, CNR1, CNR2 | HTR1A 10/4885HTR1D 18/4885HTR1B 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.